Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics reported highly positive initial data from an ongoing Phase 1/2 clinical trial testing the combination of vopimetostat, a PRMT5 inhibitor, with daraxonrasib, a RAS(ON) inhibitor, in patients with second and third line MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The combination showed a 92% obje…